Amy Ritter, PhD

Scientific Editor, BioPharm International

Articles

AstraZeneca Announces an Additional 2300 Layoffs

AstraZeneca announced further downsizing in response to an expected period of declining revenues in the face of patent expirations. The company will eliminate 2300 positions in sales and general administration.

AstraZeneca to Cut 1600 Positions in R&D Reorganization

AstraZeneca announced that it will consolidate its R&D capabilities into three centers located in Cambridge, UK; Gaithersburg, MD in the US; and M?lndal, Sweden. The reorganization will result in a net loss of 1600 position, mostly in the US and the UK.

INTERPOL and Pharma Collaborate to Fight Counterfeiting

INTERPOL and 29 of the world's largest pharmaceutical companies have joined forces in an initiative to battle counterfeit drugs.

Mylan Acquires Generic Injectables Unit From Strides Arcolab

Mylan announced that it has signed an agreement to acquire the generic injectables unit Agila Specialties from Strides Arcolab for $1.6 billion in cash.

Roche/Genentech Win FDA Approval for Antibody-Drug Conjugate

FDA approved Roche?s antibody-drug conjugate, Kadcyla (trastuzumab emtansine or T-DM1), for the treatment of people with HER2-positive metastatic breast cancer.

BARDA Continues to Support Protein Sciences' Cell-Based Vaccine Programs

Protein Sciences announced that the Biomedical Advanced Research and Development Authority (BARDA) will continue to support the company?s influenza vaccines program.

Lilly Discontinues Phase III Rheumatoid Arthritis Program

Eli Lilly and Co. announced that it will discontinue its Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, because of lack of efficacy.

FDA Lists Guidance Documents Planned for 2013

FDA has released a list of more than 50 guidance documents planned for 2013.

FDA Lists Guidance Documents Planned for 2013

FDA has released a list of more than 50 guidance documents planned for 2013.